Stability indicating HPLC method development and validation of Fostemsavir in bulk and marketed formulations by implementing QbD approach

Mahesh Deshpande; Sejal Barge; Khushabu Patil; Asmita Gaikwad; Lokesh Barde; Nitin Deshmukh

doi:10.52756/ijerr.2023.v30.030

Mahesh Deshpande Department of Pharmaceutical Quality Assurance, Amrutvahini College of Pharmacy, Sangamner, Ahmednagar, Maharashtra, India https://orcid.org/0000-0003-4367-2192
Sejal Barge Department of Pharmaceutical Quality Assurance, Amrutvahini College of Pharmacy, Sangamner, Ahmednagar, Maharashtra, India https://orcid.org/0000-0002-3051-5270
Khushabu Patil Department of Pharmaceutical Chemistry, Arunamai College of Pharmacy, Mamurabad, Jalgaon, Maharashtra, India https://orcid.org/0009-0004-1037-2585
Asmita Gaikwad Department of Pharmaceutical Chemistry, Sharadchandra Pawar College of Pharmacy, Otur, Maharashtra, India https://orcid.org/0000-0003-3287-4397
Lokesh Barde Department of Quality Assurance, S.N.D. College of Pharmacy, Babhulgaon, Tal. Yeola, Dist. Nashik, Maharashtra, India https://orcid.org/0000-0002-2308-1478
Nitin Deshmukh Department of Science and Technology, Savitribai Phule Pune University, Pune, Maharashtra, India https://orcid.org/0009-0001-1379-0465

DOI: https://doi.org/10.52756/ijerr.2023.v30.030

Keywords: Fostemsavir, HPLC, Quality Control, Quality by Design

Abstract

Background: Achieving a predictable degree of quality with intended and planned specifications is known as "quality by design." QbD (Quality-by-Design) is an alternative to conventional method development that places more attention on identifying and mitigating potential risks. Component of the Quality-by-Design methodology involves conducting a series of experiments to learn how various factors, including the dependant variables, affect the answers of interest. Here, we use a QbD (Quality-by-Design) loom to detail the creation and verification of a stability-indicating high-performance liquid chromatography (HPLC) method for Fostemsavir in both bulk and finished-goods forms.

Results:

In this work, we present a workable experimental design for optimising the RP-HPLC separation technique by identifying the optimum mobile phase concentration and flow rate. Below are the ideal chromatographic conditions as calculated by Design Expert version 13.0: Mobile phase: 80 parts acetonitrile to 20 parts formic acid (v/v), flow rate: 0.8 millilitres per minute, retention time: 3.24 minutes, column dimensions: GIST C18 (250 mm × 4.6 mm × 5.0 μm).

Here we propose a practical experimental layout for determining the optimal mobile phase concentration and flow rate for the RP-HPLC separation technique. Using Design Expert version 13.0, the optimum chromatographic conditions were determined to be as follows: Shim-pack GIST C18 (250 mm 4.6 mm, 5.0 μ), mobile phase acetonitrile to 1% formic acid (80:20, v/v), flow rate 0.8 ml/min, and retention period 3.24 min.

At a detection wavelength of 266 nm, it was discovered that the devised technique was linear over a concentration range of 50-90 μg/ml (r² = 0.997). Test parameters for the system's appropriateness were determined to be 1.124 for the tailing factor and 9480 for the theoretical plates. Intraday RSD was found to range from 0.70 to 0.94, whereas interday RSD was found to range from 0.55 to 0.95 percent. Values for robustness were under 2%. The solution stability % RSD was calculated to be 0.83. The result of the assay was 100.05 percent. The created methodologies were used to studies of forced degradation, and the stressed materials were analysed. The parameters used to validate the procedure fell within the acceptable range recommended by ICH.

Conclusion: Using Design Expert 13.0, we created a central composite design experiment that illustrates the relationships between mobile phase and flow rate across three levels, with retention duration, tailing factor, as well as theoretical plates as the responses of interest. By this work, we gain insight into the variables that affect chromatographic separation and strengthen our conviction that the HPLC method we've devised will serve our needs. Quantitative method development was applied to improve comprehension of multi-tiered method variables.

References

Bhatt, D. A., & Rane, S. I. (2011). QbD approach to analytical RPHPLC method development and its validation. International Journal of Pharmacy and Pharmaceutical Sciences, 3(1), 179-187.

Borman, P., Nethercote, P., Chatfield, M., Thompson, D., & Truman, K. (2007). The application of quality by design to analytical methods, Pharmaceutical Technology, 31(12), 142– 152.

Dhand, V., Dedania, Z., Dedania, R., & Nakarani, K. (2020). QbD approach to method development and validation of orciprenaline sulphate by HPLC. Journal of Global Trends in Pharmaceutical Sciences,11, 8634–8640.

Elder, D. P., & Borman, P. (2013). Improving analytical method reliability across the entire product lifecycle using QbD approaches. Pharmaceutical Outsourcing, 14(4), 14-19.

Galen, W.E. (2004). Analytical Instrumentation Handbook 2nd edn. Marcel Dekker Inc, New York.

Gorycki, P., Magee, M., Ackerman, P., Miao, X., & Moore, K. (2022). Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects. Xenobiotica, 52(6), 541-554. https://doi.org/10.1080/00498254.2022.2119179

Guideline, I. H. T. (2003). Stability testing of new drug substances and products. Q1A (R2), Current Step, 4(1-24).

Hanley, S., Brown, J., Timmins, P., Davies, C., & Dennis, A. (2022). Unexpected Stability of a Prodrug to Enzymatic Hydrolysis within a Hydrated HPMC Matrix Tablet. Pharmaceutics, 14(10), 2222. https://doi.org/10.3390/pharmaceutics14102222

Karadsheh, R. N. (2021). Redesign of an HIV-1 Entry Inhibitor Core Region Influences Its Kinetic and Pharmacokinetic Properties. Drexel University. https://doi.org/10.3390/molecules25061430

Karadsheh, R., Meuser, M. E., & Cocklin, S. (2020). Composition and orientation of the core region of novel HIV-1 entry inhibitors influences metabolic stability. Molecules, 25(6), 1430.

Lamichhane, S., Das, B., Adhikari, R. P., & Jeyaprakash, M. R. (2022). Overview of Forced Degradation Analysis for FDA Approved Antiretroviral agents: A Review. Journal of Young Pharmacists, 14(3), 273. https://doi.org/10.5530/jyp.2022.14.55

Meuser, M. E., Murphy, M. B., Rashad, A. A., & Cocklin, S. (2018). Kinetic characterization of novel HIV-1 entry inhibitors: discovery of a relationship between off-rate and potency. Molecules, 23(8), 1940. https://doi.org/10.3390/molecules23081940

Molnár, I., Rieger, H. J., & Monks, K. E. (2010). Aspects of the “Design Space” in high pressure liquid chromatography method development. Journal of Chromatography A, 1217(19), 3193-3200. https://doi.org/10.1016/j.chroma.2010.02.001

Monks, K., Molnár, I., Rieger, H. J., Bogáti, B., & Szabó, E. (2012). Quality by design: multidimensional exploration of the design space in high performance liquid chromatography method development for better robustness before validation. Journal of Chromatography A, 1232, 218-230. https://doi.org/10.1016/j.chroma.2011.12.041

Myers, R., Montgomery, D., Anderson-Cook, C. (2016) Response surface methodology: process and product optimization using designed experiments. 4th edn. New York: Wiley.

Orlandini, S., Pinzauti, S., & Furlanetto, S. (2013). Application of quality by design to the development of analytical separation methods. Analytical and Bioanalytical Chemistry, 405, 443-450. https://doi.org/10.1007/s00216-012-6302-2

Patel, S., & Patel, N. J. (2009). Simultaneous RP-HPLC and HPTLC estimation of fluoxetine hydrochloride and olanzapine in tablet dosage forms. Indian Journal of Pharmaceutical Sciences, 71(4), 477. https://doi.org/10.4103/0250-474X.57306

Rajkotwala, A. S., Shaikh, S. S., Dedania, Z., Dedania, R., & Vijyendraswamy, S. (2016). QbD approach to analytical method development and validation of piracetam by HPLC. World Journal of Pharmacy and Pharmaceutical Sciences, 5(5), 1771-1784.

Ramalingam P., Bhadraya, K., & Padmanabha Reddy, Y. (2015). Analytical quality by design: a tool for regulatory flexibility and robust analytics. International Journal of Analytical Chemistry, 2015. https://doi.org/10.1155/2015/868727

Rebensburg, S., Helfer, M., Schneider, M., Koppensteiner, H., Eberle, J., Schindler, M., Gürtler, L. & Brack-Werner, R. (2016). Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins. Scientific Reports, 6(1), 1-15. https://doi.org/10.1038/srep20394

Reid, G. L., Cheng, G., Fortin, D. T., Harwood, J. W., Morgado, J. E., Wang, J., & Xue, G. (2013). Reversed-phase liquid chromatographic method development in an analytical quality by design framework. Journal of Liquid Chromatography & Related Technologies, 36(18), 2612-2638. https://doi.org/10.1038/srep20394

Roy, S. (2012). Quality by design: A holistic concept of building quality in pharmaceuticals. International Journal of Pharmaceutical and Biomedical Research, 3(2), 100-108.

Schweitzer, M., Pohl, M., Hanna-Brown, M., Nethercote, P., Borman, P., Hansen, G., & Larew, J. (2010). Implications and opportunities of applying QbD principles to analytical measurements. Pharmaceutical Technology, 34(2), 52-59.

Singh, P., Maurya, J., Dedania, Z., & Dedania, R. (2017). QbD Approach for stability indicating HPLC method for determination of artemether and lumefantrine in combined dosage form. Int. J. Drug Reg. Affairs, 5, 44-59. https://doi.org/10.22270/ijdra.v5i4.209

Smith, J., Jones Jr, M., & Houghton, L. (1999). Future of health insurance. N. Engl. J. Med., 965, 325-329.

Snyder, L. R., Kirkland, J. J., & Glajch, L. J. (1997). Basics of Separation; Practical HPLC Method Development, John Willey and Sons. Inc, New York, 2nd end, pp. 5-17. https://doi.org/10.1002/9781118592014

The International Conference on Harmonisation ICH (2005). Technical Requirements for Registration of Pharmaceuticals for Human Use on Quality Risk Management Q9.

The International Conference on Harmonisation ICH (2005) Technical Requirements for Registration of Pharmaceuticals for Human Use on Validation of Analytical Procedures: Text and Methodology Q2(R1).

The International Conference on Harmonisation ICH (2008) Technical Requirements for Registration of Pharmaceuticals for Human Use on Pharmaceutical Quality System Q10.

The International Conference on Harmonisation ICH (2009) Technical Requirements for Registration of Pharmaceuticals for Human Use on Pharmaceutical Development Q8(R2).

The International Conference on Harmonisation ICH (2012) Technical Requirements for Registration of Pharmaceuticals for Human Use on Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/ Biological Entities) Q11.

Thoueille, P., Seybold, U., Decosterd, L. A., & Desfontaine, V. (2023). Development and validation of a liquid chromatography coupled to tandem mass spectrometry method for the monitoring of temsavir plasma concentrations in people living with HIV. Journal of Chromatography B, 1214, 123575. https://doi.org/10.1016/j.jchromb.2022.123575

Turpin, J., Patrick, H., Lukulay, Verseput, R., Krull, I.S., & Swartz, M.E. (2008). A quality-by-design methodology for rapid LC method development, part I. LCGC North America, 26 (12), 1190–1197.

Turpin, J. Patrick, H., Lukulay, Verseput, R., Krull, I.S., & Swartz, M.E. (2009). A quality-by-design methodology for rapid LC method development part II. LCGC North America, 27(1), 48–61.

Yubing, T. (2011). Quality by design approaches to analytical methods- FDA perspective.